Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.